Created by medical experts Tested to the highest standard GMP Certified Made in the USA This statement has not been evaluated by the Food and Drug Administration
NKF KDOQI GUIDELINES KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification Figures Figure 1 Evidence Model for Stages in the Initiation and Progression of Chronic Kidney Disease and Therapeutic Interventions Figure 2 Incidence and Prevalence of End-Stage Renal Disease in the US Figure 3 Evidence Model for Stages in the Initiation and Progression of Cardiovascular Disease and Therapeutic Interventions Figure 4 Kidney Function Decline in Chronic Kidney Disease Figure 5 Creatinine Distribution: US Population Age 20 by Sex Figure 6 Cardiovascular Mortality in the General Population (NCHS) and in ESRD Treated by Dialysis (USRDS) Figure 7 Prevalence of Albuminuria and High Blood Pressure (%) in US Adults Age 20 Years, NHANES III, 1988-1994 Figure 8 Distribution of Albumin-to-Creatinine Ratio in US Men and Women, Age 20 Years: NHANES III, 1988-1994 Figure 9 GFR vs
Patusco, R
C., Haber, D
Moreover, for muscle-to-bone reattachment, BPC 157 therapy has had its special muscle healing and function recovery reviewed in detail (musclebrain axis), specifically recovering and maintaining the function and integrity of the striated, heart, and smooth muscles, along with the recovery of the prime injury and muscle weakness as part of the peripheral and central effect (for review see [11,12])
